GlaxoSmithKline's bid to tackle neglected diseases receives a muted response from the rest of the industry.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional information
Additional reporting by Natasha Gilbert
Related links
Related links
Related links in Nature Research
Supplement: A World of Science in the Developing World
Commentary: New uses for old drugs
Commentary: Neglected tests for neglected patients
Commentary: Experiments in social responsibility
Related external links
MSF Campaign for Access to Essential Medicines
Drugs for Neglected Diseases Initiative
Rights and permissions
About this article
Cite this article
Butler, D. Drug patent plan gets mixed reviews. Nature 457, 1064–1065 (2009). https://doi.org/10.1038/4571064a
Published:
Issue Date:
DOI: https://doi.org/10.1038/4571064a
This article is cited by
-
Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery
Nature Reviews Drug Discovery (2009)
